Exploration of predictive biomarkers for postoperative recurrence of stage <scp>II</scp>/<scp>III</scp> colorectal cancer using genomic sequencing
-
- Fumishi Kishigami
- Division of Cellular Signaling National Cancer Center Research Institute Tokyo Japan
-
- Yosuke Tanaka
- Division of Cellular Signaling National Cancer Center Research Institute Tokyo Japan
-
- Yoko Yamamoto
- Department of Surgical Oncology The University of Tokyo Tokyo Japan
-
- Toshihide Ueno
- Division of Cellular Signaling National Cancer Center Research Institute Tokyo Japan
-
- Shinya Kojima
- Division of Cellular Signaling National Cancer Center Research Institute Tokyo Japan
-
- Kazuhito Sato
- Department of Surgical Oncology The University of Tokyo Tokyo Japan
-
- Satoshi Inoue
- Division of Cellular Signaling National Cancer Center Research Institute Tokyo Japan
-
- Saori Sugaya
- Division of Cellular Signaling National Cancer Center Research Institute Tokyo Japan
-
- Soichiro Ishihara
- Department of Surgical Oncology The University of Tokyo Tokyo Japan
-
- Hiroyuki Mano
- Division of Cellular Signaling National Cancer Center Research Institute Tokyo Japan
-
- Masahito Kawazu
- Division of Cellular Signaling National Cancer Center Research Institute Tokyo Japan
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>Postoperative recurrence of colorectal cancer (CRC) eventually leads to therapeutic failure; therefore, treatment strategies based on accurate prediction of recurrence are urgently required. To identify biomarkers that can predict treatment outcomes, we compared the mutational profiles of surgically resected specimens from patients with recurrent cancer with those from patients with non‐recurrent cancer. Target sequencing, whole‐exome sequencing (WES), or whole‐genome sequencing (WGS) was performed on 89 and 58 tumors from recurrent and non‐recurrent cases, respectively. WGS revealed the driver mutations that were not detected with target sequencing or WES, including the structural variations affecting <jats:italic>ZFP36L2</jats:italic>. Loss of function of <jats:italic>ZFP36L2</jats:italic> was frequently observed in primary tumors from recurrent cases. Furthermore, the recurrence‐free survival of patients with loss of function of <jats:italic>ZFP36L2</jats:italic> was significantly shorter relative to patients with no loss of <jats:italic>ZFP36L2</jats:italic> function. In summary, the study demonstrated that detailed genomic analysis could help improve precision medicine for CRC.</jats:p>
収録刊行物
-
- Cancer Medicine
-
Cancer Medicine 11 (18), 3457-3470, 2022-03-28
Wiley